• Last updated：2024-08-19
• Count Views：16

        In order to enable manufacturers to more successfully achieve framework integrity in the statement of the value of a new drug and legitimacy in the forecast of financial impacts while planning or preparing materials to be submitted for review of the NHI coverage application of a new drug, the Center particularly introduced the “HTA Payment Advisory Service” in October 2021. In 2022, a total of 6 paid consultation cases were closed. All applicants were foreign-capital manufacturers and all proposals consulted about were C in classification. By the category of the drug consulted about, 1 was new composition, 1 revision of payment criteria and 4 local pharmacoeconomics research in nature.